IBEX 35
11.105,50 +55,40 (+0,50%) Euro Stoxx 50
5.085,08 +30,67 (+0,61%) Dólar/Euro
1,0772 -0,0012 (-0,11%) Petróleo Brent
82,73 -1,15 (-1,37%) Oro
2.366,90 +26,60 (+1,14%) Bitcoin EUR
56.993,23 +357,95 (+0,63%)
Silence Therapeutics plc (SLN)
Después del cierre:
Silence Therapeutics plc
72 Hammersmith Road
London W14 8TH
United Kingdom
44 20 3457 6900
https://www.silence-therapeutics.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 109
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Craig A. Tooman M.B.A. | President, CEO & Executive Director | 1,47M | N/A | 1965 |
| Ms. Rhonda L. Hellums | CFO & Secretary | 895,39k | N/A | 1973 |
| Dr. Steven J. Romano M.D. | Head of Research & Development | 654,01k | N/A | 1959 |
| Dr. Marie Wikstrom Lindholm Ph.D. | Chief Scientific Officer | N/A | N/A | N/A |
| Ms. Gem Gokmen Hopkins | Head of IR & Corporate Communications | N/A | N/A | N/A |
| Dr. Barbara A. Ruskin J.D., Ph.D. | Senior VP and Chief Intellectual Property & Innovation Officer | N/A | N/A | 1961 |
| Dr. Eric Floyd M.B.A., M.S., Ph.D. | Senior Vice President of Regulatory Affairs & Quality Assurance | N/A | N/A | 1963 |
| Mr. J.P. Gabriel | Chief Technical Operations Officer | N/A | N/A | N/A |
| Mr. Curtis Rambaran M.D. | Chief Medical Officer | N/A | N/A | N/A |
Descripción
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.
Gobierno corporativo
El ISS Governance QualityScore de Silence Therapeutics plc, a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.
